Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2021 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...
October 04, 2021 07:54 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Launch of its Initial Public Offering

PURCHASE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...
April 20, 2021 11:31 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board

Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage...
March 03, 2021 08:01 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference

New York, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
February 10, 2021 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology

Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
February 01, 2021 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology

PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
January 05, 2021 09:44 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance

Pittsburgh, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
October 27, 2020 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors

Pittsburgh, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
October 19, 2020 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

Pittsburgh, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
September 09, 2020 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors

Pittsburgh, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...